TET2 and myeloproliferative disorder: A stepwise increase in TET2 gene mutations in MPN was observed with subsequent versions of the WHO classification and diagnostic criteria among all cases of MPN (12.9% for WHO criteria 2001, 14.5% for WHO criteria 2008 and 20.1% for WHO criteria 2016), PV (13.7% for WHO criteria 2001, 16.9% for WHO criteria 2008 and 21.4% for WHO criteria 2016) and ET (5.3% for WHO criteria 2001, 9.4% for WHO criteria 2008 and 20.3% for WHO criteria 2016) but not in MF (17.5% for WHO criteria 2001, 14.4% for WHO criteria 2008 and 16.5% for WHO criteria 2016).